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A B S T R A C T
Age related macular degeneration (AMD) is a progressive, neurodegenerative disorder that leads to the severe
loss of central vision in elderlies. The health of retinal pigment epithelial (RPE) cells is critical for the onset of
AMD. Chronic oxidative stress along with loss of lysosomal activity is a major cause for RPE cell death during
AMD. Hence, development of a molecule for targeted lysosomal delivery of therapeutic protein/drugs in RPE
cells is important to prevent RPE cell death during AMD. Using human RPE cell line (ARPE-19 cells) as a study
model, we conﬁrmed that hydrogen peroxide (H2O2) induced oxidative stress results in CD44 cell surface re-
ceptor overexpression in RPE cells; hence, an important target for speciﬁc delivery to RPE cells during oxidative
stress. We also demonstrate that the known nucleic acid CD44 aptamer - conjugated with a ﬂuorescent probe
(FITC) - is delivered into the lysosomes of CD44 expressing ARPE-19 cells. Hence, as a proof of concept, we
demonstrate that CD44 aptamer may be used for lysosomal delivery of cargo to RPE cells under oxidative stress,
similar to AMD condition. Since oxidative stress may induce wet and dry AMD, both, along with proliferative
vitreoretinopathy, CD44 aptamer may be applicable as a carrier for targeted lysosomal delivery of therapeutic
cargoes in ocular diseases showing oxidative stress in RPE cells.
1. Introduction
Age related macular degeneration (AMD) is a progressive, neuro-
degenerative disorder that leads to the loss of central vision in elderly
people [1]. The hallmarks of the disease include age related retinal
changes in photoreceptors, retinal pigment epithelium (RPE), and
Bruch's membrane. The health of RPE cells, which plays an important
role in maintenance and homeostasis of the retina, is critical for the
onset of AMD. AMD is classiﬁed to two forms: the wet form involves
choroidal neovascularization (CNV), and the dry form is associated with
geographic atrophy (GA). Either of the two forms may eventually lead
to the death of RPE cells, which ultimately results in the death of
photoreceptors and gradual loss of vision. Though AMD is a multi-
factorial disorder, the most common reason for dry AMD is oxidative
stress whereas the wet form is mainly caused by inﬂammation, which
may itself be induced by oxidative stress [1]. This oxidative stress is
generated in RPE cells due to substantial consumption of oxygen,
accumulation of lipid peroxidation products from ingested photo-
receptor outer segments, and constant exposure to light. Clinical studies
have also shown that dry AMD may develop into wet AMD, hence, it is
important to develop therapeutic interventions at the early stage of dry
AMD to avoid progression to the more aggressive wet form of the dis-
ease.
Lysosomal activity is crucial for the health of RPE cells since it
degrades aggregated or misfolded proteins [2]. Reduced lysosomal ac-
tivity and chronic oxidative stress in the RPE cells was observed in
clinical AMD cases [3]. Hence, restoring the lysosomal activity of the
RPE cells to minimize AMD pathogenesis was earlier suggested [2] and
experimentally proven in the cultured RPE cells by Subrizi et al. [4].
Thus, targeting therapeutic proteins/drugs to lysosomes of RPE cells for
overcoming lysosomal inactivity is an important aspect of ocular drug
delivery for the treatment of AMD. Even though several attempts have
been made earlier for drug delivery into the RPE cells using nano-
particles [5], there is a dearth of systems that speciﬁcally target a drug
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The CD44 receptor is a cell surface glycoprotein which is known to
be upregulated in some cancers [6], however its expression in RPE cells
has been sparsely studied. The CD44 receptor is not expressed in post-
mitotic RPE cells [7], but its upregulation in the RPE during in-
ﬂammation has been seen in a laser induced CNV rat model [8], and in
the RPE cells of ﬁbrotic human retina [7]. The overexpression of cell
adhesion molecules, including CD44, in RPE cells has been linked to the
initiation of choroidal neovascularization in the laser induced CNV rat
model [8]. Interestingly, overexpression of CD44 due to oxidative stress
has been observed in a gastric epithelium cell line [9], though, no
conclusive study has been conducted to study the direct eﬀect of oxi-
dative stress on CD44 expression in RPE cells in vitro or in vivo. Since
oxidative stress is the underlying cause of dry AMD and one of the
factors responsible for multifactorial wet AMD, we decided to study the
eﬀect of oxidative stress on CD44 expression in the RPE cells, so that it
may be used as a suitable target during oxidative stress for receptor
mediated selective drug delivery with a previously reported nucleic
acid CD44 aptamer - speciﬁc for hyaluronic acid binding domain
(HABD) of the CD44 protein [10]. HABD is a conserved domain that is
found in all the splice variants of CD44 gene. Aptamers are small,
structurally distinct oligonucleotides that exhibit speciﬁc and high
binding aﬃnities to proteins and other biological macromolecules be-
cause of their distinct 3D folding [11]. Due to their ability for easy
chemical modiﬁcation, ease of synthesis, low immunogenicity, low
batch-to-batch variation and high stability they are attractive ligands in
the ﬁeld of targeted therapeutics and diagnostics.
The objective of this work was to develop a delivery method that
targets the RPE cells and, in particular, lysosomes within the RPE to
overcome lysosomal ineﬃciency. We investigated this CD44 receptor-
based system as a potential cell surface target molecule for targeting
drug(s) to the diseased RPE cells, speciﬁcally during the oxidative
stress. The cellular uptake of this system is based on speciﬁc receptor-
mediated endocytosis of the ligand-label or ligand-drug conjugate. We
demonstrate here the proof-of-concept for CD44 based targeted delivery
into the diseased RPE cells.
2. Material & methods
2.1. Cell culture
ARPE-19 cells (human retinal pigment epithelial cell line, ATCC
CRL-2302) were cultured as explained earlier [4]. For experiments
where diﬀerentiated ARPE-19 cells were required, cells were seeded at
high density (1.5× 105 cells/cm2) in a low serum media (2% FBS).
Cells were allowed to diﬀerentiate for 4 weeks at 37 °C in 7% CO2 in a
humidiﬁed incubator. Other constituents were kept the same. MDA-MB-
231 and NIH-3T3 cells were grown in DMEM-F12 and DMEM media,
respectively, supplemented with 10% FBS, 2mM L-glutamine and an-
tibiotics at 37 °C in 5% CO2 incubator.
2.2. Protein extraction and western blotting
Cells were harvested in lysis buﬀer (50 mM Tris, pH 7.6, 150 mM
NaCl, 0.1% SDS, 1% NP-40, and 2 mM EDTA + protease inhibitor
cocktail (Roche)) followed by sonication (5 min, medium power) and
15-min incubation on ice for cell lysis. Next, centrifugation was per-
formed for 15 min at 14000 g and supernatant containing total cell
extract (TCE) was collected for study. Protein concentration was mea-
sured by Bradford assay (Bio-Rad) with BSA as a standard. TCE was
loaded on 10% acrylamide gel followed by SDS-PAGE. Rabbit anti-
CD44 (1:1000; Abcam) and mouse anti–β-actin (1:2000; Cell signaling)
antibodies were used with HRP-conjugated secondary antibodies for
western blotting, and the blots were imaged using the Biorad Image Lab
imaging system. Blots were cut to enable blotting for multiple anti-
bodies. Densitometric analysis was performed using ImageJ and
statistical analysis was performed using Prism6 software.
2.3. CD44 expression during oxidative stress
ARPE-19 cells (1.5× 105 cells/cm2) were seeded in a ﬂat bottom 6
well plate (Nunc) and allowed to diﬀerentiate for 28 days in a low
serum (2% FBS) media. Hydrogen peroxide (Sigma cat. no. 516813)
was added to cells grown in above described media at an increasing
concentration of 0, 0.50, 0.75, 1, 1.25, 1.5 and 2mM, respectively, to
induce oxidative stress. After 24 h of introducing oxidative stress, the
old media was replaced with fresh dilutions of H2O2 and kept for 24 h
more. Thus, oxidative stress was given for a total of 48 h. Total cell
extract was prepared as described above and stored in −20 °C freezer
until use. Total cell extract was loaded in equal quantity (30ug) on 10%
acrylamide gel for SDS-PAGE. Western blot was performed as described
above.
2.4. Aptamer surface-binding/internalization in cell lines
Proliferating ARPE-19 cells along with CD44 positive (MDA-MB
231) and CD44 negative (NIH-3T3) cell lines were seeded on glass
coverslips placed in 24 well plates (Nunc) a day before experiment. All
the three cell lines were treated with either FITC-CD44 aptamers or
FITC-scramble aptamers (200 nM ﬁnal concentration) for 90min at
37 °C in a CO2 incubator to allow binding and/or internalization of
aptamers. Subsequently, cells were rinsed once each with ice-cold PBS
followed by 0.5 N NaCl (ice-cold) to remove unbound or weakly bound
FITC-CD44 aptamer from cell surface. Next, a PBS wash was given
followed by ﬁxation using 4% paraformaldehyde for 10min. For vi-
sualization of CD44 glycoprotein cells were permeabilized with 0.1%
Triton for 10min, followed by blocking (5% BSA in 0.1% Triton X-100)
for an hour. CD44 primary Ab (Abcam) in blocking solution was in-
cubated with cells at 4 °C overnight followed by washing with PBS.
Finally, cells were incubated with Alexa-594 labelled goat anti-mouse
secondary antibody (Cell Signaling) for an hour at room temperature.
Nucleus was counterstained with Hoechst. Imaging was done using
Leica DM6000 microscope using 20× objective with an optical mag-
niﬁcation of 1.6X. Cells showing aptamer labeling were counted
manually using ImageJ software. Speckles (green) showing CD44-FITC
aptamer were counted from each ﬁeld, and divided with total number
of cells in the same ﬁeld (i.e., denoted by stained nuclei), thus, giving
average aptamers/cell count. The Graph plotted represents quantitative
analysis of surface bound or internalized scramble- and CD44-aptamers
for each cell line from an experiment performed in triplicate. n=≥
100 cells from 4 diﬀerent ﬁelds.
2.5. FITC-CD44 aptamer intracellular distribution
Proliferating ARPE-19 cells were seeded on glass coverslip placed in
24-well plate (Nunc) at a density of 5.2× 104 cells/cm2 two days be-
fore the uptake experiment. 24 h post cell seeding, lysosomes and late-
endosomes were stained with CellLight Lysosome/Late Endosomes-RFP
reagent (Molecular Probes) following the manufacturer's protocol and
the cells were returned to the incubator for 16 h. On the day of ex-
periment, cells were incubated with FITC-CD44 aptamer (200 nM) for
90min at 37 °C in a 7% CO2 incubator. Subsequently, the cells were
rinsed once each with ice-cold PBS followed by 0.5 N NaCl (ice-cold) to
remove unbound or weakly bound FITC-CD44 aptamer. Again a PBS
wash was given followed by ﬁxation using 4% paraformaldehyde for
10min at room temperature. Cells were again washed with PBS, treated
with Hoechst for nuclear staining and mounted using antifade diamond
mounting media (Molecular Probes). Imaging was done by Leica TCS
SP5 confocal microscope using 60× (glycerol) objective.
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3. Results
3.1. CD44 receptor is overexpressed during oxidative stress in RPE cells
CD44 surface receptor is a well-known biomarker for certain can-
cers and cancer stem cells, however its expression pattern has not been
studied in the RPE cells under oxidative stress, which is an important
factor in the development of AMD. Hence, we validated CD44 cell
surface receptor as a suitable target molecule for targeted delivery to
RPE cells under oxidative stress. For this purpose a human RPE cell line,
i.e., ARPE-19 cells were used as a study model. Proliferating ARPE-
19 cells are known to express CD44 protein, unlike post mitotic RPE
cells which do not express this protein [8,12,13]. This was conﬁrmed by
Western blot (WB) analysis (Supplementary Fig. S1). CD44 expressing
MDA-MB-231 cells were used as a positive control, and NIH-3T3 cells
were used as a negative control. To obtain a more relevant cellular
condition we diﬀerentiated ARPE-19 cells for 4 weeks in low serum (2%
FBS), to downregulate the expression of CD44 receptors
(Supplementary Fig. S2). Similar downregulation of CD44 in diﬀer-
entiated ARPE-19 cells has been reported earlier [12]. Next, to induce
oxidative stress on diﬀerentiated ARPE-19 cells, an increasing con-
centration of hydrogen peroxide (H2O2) was added to the cells (0–2mM
for 48 h) followed by Western blot from the total cell extract. H2O2
concentration at 2.5mM and above resulted in visible stress and death
of ARPE-19 cells - presumably due to oxidative stress, hence, not con-
sidered for analysis (Supplementary Fig. S3). Increased oxidative stress,
i.e., 0–2mMH2O2 resulted in upregulation of CD44 in diﬀerentiated
ARPE-19 cells (Fig. 1). This observation may be translated to the in vivo
condition where oxidative stress in ageing RPE cells might lead to an
overexpression of CD44 cell surface receptor, in AMD patients.
3.2. Speciﬁc binding of CD44 aptamer to ARPE-19 cells
To study the speciﬁcity of CD44 aptamer to proliferating ARPE-
19 cells we compared it with CD44 positive (MDA-MB-231) and CD44
negative (NIH-3T3) cell lines by immunoﬂuorescence. Proliferating
ARPE-19 cells – due to constitutive expression of CD44 glycoprotein -
were used as an alternative for post-mitotic RPE cells under oxidative
stress, as a proof-of-concept model, to conﬁrm the FITC conjugated
CD44 aptamer surface binding and/or internalization.
Here, the ﬂuorescent probe FITC was conjugated as cargo to the
aptamer to demonstrate and visualize the cellular delivery of aptamer.
Each aptamer is conjugated to single FITC molecule at 5’ terminal. For
quantitative analysis, wideﬁeld ﬂuorescence imaging was performed.
The ﬂuorescent signal (i.e., each signal representing an aptamer) in
each cell in a visual ﬁeld was counted (Fig. 2a). Total number of signal
counts were averaged as per cell count from atleast hundred cells
(Fig. 2b). Maximum internalization or surface binding of FITC-CD44
aptamer was observed in ARPE-19 cells, presumably due to high
CD44 cell surface receptor expression (as shown in Supplementary Fig.
S1). Though MDA-MB-231 cells express CD44 receptor, it had less
signal as compared to ARPE-19 cells. NIH-3T3 cells showed the lowest
signal for CD44 aptamer. Infact, many NIH-3T3 cells had no ﬂuorescent
aptamer signal. The signal in some negative control NIH-3T3 cells is
probably due to the internalization by non-receptor mediated en-
docytosis. ARPE-19 cells demonstrated approximately nine-fold inter-
nalization of FITC-CD44 aptamers in comparison to negative control
NIH-3T3 cells. Scrambled aptamer internalization by NIH-3T3, MDA-
MB-231 and ARPE-19 cells was signiﬁcantly low. Higher internalization
of scrambled aptamer by ARPE-19 cells may be explained by the pha-
gocytic nature of the RPE cells as compared to the other cells in this
study. However, in ARPE-19 cells CD44-aptamer internalization was
four fold higher as compared to scramble aptamer, thus demonstrating
the role of CD44 receptor mediated internalization. Hence, this result
shows that CD44 aptamer has a potential to deliver conjugated cargo to
CD44 positive ARPE-19 cells.
3.3. Internalization of CD44 aptamer to lysosomes
The intracellular localization of the internalized aptamer is im-
portant because it may determine the therapeutic eﬀects of the con-
jugated cargo. Hence, we studied qualitatively the localization of in-
ternalized FITC conjugated CD44 aptamer in proliferating ARPE-
19 cells. To this aim, we stained the late-endosomes and lysosomes of
proliferating ARPE-19 cells with CellLight Endosome-RFP and CellLight
Lysosome-RFP, respectively. Subsequent incubation with FITC-CD44
aptamer showed signiﬁcant localization of CD44 aptamer (green) in
late endosomes and lysosomes (red) (Fig. 3).
4. Discussion
Protein misfolding, aggregation and abnormal degradation are
Fig. 1. Upregulated CD44 expression due to oxidative stress in ARPE-
19 cells. Diﬀerentiated ARPE-19 cells (DIV28) were treated with increasing
concentration of H2O2 (0, 0.50, 0.75, 1.0, 1.25, 1.50, and 2.0 mM) for 48 h (a)
Figure shows cropped blot that is a representation of three independent ex-
periments. Blots from a single membrane were cut after protein transfer, and
incubated with diﬀerent antibodies for evaluation. All gels were run in the same
experimental conditions (see material and methods for details) (Full-length
blots of each tested protein are reported in Supplementary Fig. S3). WB result
shows increasing level of CD44 protein expression with increase in H2O2 con-
centration. CD44 expression is determined by anti-CD44 antibody, and β–actin
is used as a loading control (b) Graph represents increase in CD44 expression in
H2O2 treated ARPE-19 cells in comparison to untreated cells (0 mM). Untreated
(0 mM) cells were used to normalize treated cells (0.50, 0.75, 1.0, 1.25, 1.50
and 2.0 mM) to obtain the fold change in CD44 expression. Statistical analysis is
performed using Prism6 software. Histogram is the mean ± standard deviation
of three independent experiments. p-value displayed was calculated using or-
dinary one way ANOVA followed by Dunnett's multiple comparisons test, with a
single pooled variance. * = p ≤ 0.05 is considered statistically signiﬁcant,
n = 3. DIV – Days in vitro, WB - Western blot.
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central to many neurodegenerative diseases, including AMD. Eﬀective
lysosomal activity plays an important role in abnormal protein de-
gradation and, hence, in maintaining the health of RPE cells. However,
during chronic oxidative stress RPE cells are known to lose their
lysosomal eﬃciency [3,4]. There is also a dearth of targeting systems
that deliver a therapeutic cargo to RPE cells, particularly to lysosomes
to overcome the lysosomal ineﬃciency. The only eﬀorts for targeted
delivery of a cargo to RPE cells have been done using hyaluronan [14],
Fig. 2. ARPE-19 cells internalize FITC labelled CD44 aptamer. ARPE-19 cells, along with CD44 positive (MDA-MB 231) and CD44 negative (NIH-3T3) cell lines,
were treated with FITC labelled CD44 aptamers for 90min to allow surface binding and/or internalization of aptamers. Cells showing aptamer labeling were counted
manually. Figure (a) shows NIH-3T3, MDA-MB-231 and ARPE-19 cells that bind or internalize CD44 aptamer (green). CD44 expression in cell lines is shown by
labeling with CD44 Ab (red) and nucleus is stained with Hoechst (blue). (b) Graph represents quantitative analysis of internalized or surface bound CD44−or
scramble-aptamers for each cell line from 4 diﬀerent ﬁelds. n=≥ 100 cells. Experiment was performed in triplicate. Scale bars are 50 μm.
Fig. 3. Intracellular localization of FITC-CD44
aptamer in proliferating ARPE-19 cells. FITC-
CD44 aptamer (green) was incubated with the cells
for 90min, immediately thereafter the cells were
rinsed with 0.5 N NaCl followed by ﬁxation. Top
view alongwith vertical and horizontal orthogonal
sections show colocalization of FITC-CD44 aptamer
with late endosomes (a) and lysosomes (b). Late en-
dosomes and lysosomes (red) were stained with
CellLight RFP reagent. Nucleus counterstained with
Hoechst (blue). Imaging by Leica TCS SP5 confocal
microscope using 63× objective. Scale bars are
10 μm.
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however, using hyaluronan for targeted delivery has its own limitations
[15]. Here, we show CD44 cell surface receptor as a novel target mo-
lecule for RPE cells under oxidative stress, and validate the use of CD44
aptamer for lysosomal targeting in RPE cells to prevent AMD.
This study identiﬁes CD44 cell surface glycoprotein as a novel target
molecule for RPE cells that are in oxidative stress since this receptor is
not expressed in either fetal or adult post-mitotic human RPE cells. An
earlier study shows a contradictory result and demonstrates CD44
transcript downregulation in an acute hyperoxia-induced mouse model
by microarray analysis [16]. However, that study used RPE/choroid
instead of RPE cells alone derived from a rodent model, and the study
was done at transcriptome level which might explain the diﬀerence
from our results. The same research group earlier studied the eﬀect of
oxidative stress on ARPE-19 cells using three diﬀerent oxidative stress
inducing agents, and did not report CD44 among the list of diﬀeren-
tially regulated genes [17]. In comparison, we studied the eﬀect of
oxidative stress on a diﬀerentiated human RPE cell line alone, i.e.,
ARPE-19 cells at protein level. Earlier studies have discussed the dis-
parity in mRNA and protein level expression in various diseases [18],
but the protein levels are the most important in the disease [19].
Overall, it seems that CD44 receptor expression is upregulated in the
presence of oxidative stress. For clinical signiﬁcance, this ﬁnding
should be conﬁrmed in the eyes of the AMD patients. Since CD44 is
absent in post-mitotic human RPE cells, but overexpressed in the pa-
thologic condition (during oxidative stress), it may be used as a target
for receptor-mediated delivery of therapeutic agents to RPE cells.
Secondly, this is the ﬁrst study that shows the ability of CD44 ap-
tamer in targeted delivery of cargo to the lysosomes of RPE cell.
Previous studies on targeting molecules for lysosomal drug delivery are
either not speciﬁc to RPE cells [20,21] or, if speciﬁc to RPE cells, the
lysosomal delivery was not studied [14,22]. We attached a FITC-
ﬂuorophore, analogous to a small molecule drug (e.g. shikonin that
elevates chaperone protein expression in cells) [23] to CD44 aptamer,
thus, demonstrating the ability of the CD44 aptamer to deliver con-
jugated molecules to the RPE cells. However, conjugation chemistry
that enables the release of the drug from CD44 aptamer in the lysosome
should be used for eﬀective lysosomal release [24]. The lysosomal lo-
calization of CD44 aptamers is supported by an earlier study as well,
where LRP-1 protein facilitated lysosomal localization of CD44 receptor
in tumor cells [25]. Possibly, after the binding of CD44 aptamer to
CD44 receptor, it might be localized to lysosomes of RPE cells through
the LRP-1 dependent mechanism. An earlier work has demonstrated the
importance of delivery of a therapeutic chaperone protein to the lumen
of lysosomes in overcoming a lysosomal ineﬃciency disorder [26].
Since RPE cells in AMD also suﬀer from lysosomal ineﬃciency, we need
an eﬃcient molecule that can deliver the drugs to lysosome lumen ef-
ﬁciently and we demonstrate the applicability of CD44 aptamer for this
purpose. Hence, localization of CD44 aptamer to lysosomes is of high
signiﬁcance since it may help in targeted delivery of conjugated ther-
apeutic proteins/drugs to the lysosomes of RPE cells during chronic
oxidative stress, thus, overcoming lysosomal ineﬃciency induced pa-
thogenesis during AMD [3]. Also, due to smaller size, it may have better
penetration across the inner limiting membrane (ILM).
Hyaluronic acid, a well known ligand of the CD44 receptor is in-
ternalized and transported to the lysosomes for degradation [27].
However, the fate of a receptor bound ligand might vary depending on
the ligand and its molecular weight. Though we know that CD44 ap-
tamer is localized to the lysosome in ARPE-19 cells, its fate towards
degradation is to be studied. However, whether the CD44 aptamer is
degraded in lysosomes is not a matter of concern since its role is only to
work as a carrier for delivering the conjugated therapeutic cargo to the
lysosome. Hence, it would be more important to study whether the
conjugated therapeutic cargo i.e., a drug or a therapeutic protein would
be functional after targeted delivery to the lysosome - facilitated by
CD44 aptamer. This can be veriﬁed by a follow-up study where ther-
apeutic eﬃcacy of CD44 aptamer-drug conjugate would be studied
against a control in RPE cells during oxidative stress in vitro. Though
liposomes and nanoparticles are known to localize in lysosomes of RPE
in some studies, CD44 aptamer may increase their bioavailability and
speciﬁcity due to receptor-mediated endocytosis. This statement is
supported by earlier studies that demonstrate that aptamer conjugation
to nanoparticles and liposomes increases their bioavailability in cancer
cells [11].
In summary, CD44 aptamer may be an eﬀective carrier molecule for
targeted delivery of therapeutic agents to the lysosomes of RPE cells to
overcome lysosomal ineﬃciency during oxidative stress in AMD pa-
tients. Also, it might be useful in targeted drug delivery to the RPE cells
in other ocular disorders that involve oxidative stress, such as pro-
liferative vitreoretinopathy.
Author contributions
M.N. conceived the project. C.C., M.N. and A.U. designed experi-
ments. C.C. and U.C. conducted experiments. C.C., M.G.C., LN.G. A.U.
and M.N. analyzed data and wrote the manuscript. M.N. and A.U.
provided reagents for the project.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This work was supported by the Indo-Finland research grant (IV4SP-
FinSynBio - Synthetic Biology), funded by Department of
Biotechnology, Government of India (Grant number BT/IN/Finland/
29/MN/2013). Prof. Urtti's research was supported by the Academy of
Finland, Government of Finland (Grant numbers 272597 and 303884)
and Government of Russian Federation Mega-Grant 14.W03.031.0025
“Biohybrid technologies for modern biomedicine”.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbrep.2019.100642.
References
[1] K. Zhang, L. Zhang, R.N. Weinreb, Ophthalmic drug discovery : novel targets and
mechanisms for retinal diseases and glaucoma, Nat. Rev. Drug Discov. 11 (2012)
541–559 https://doi.org/10.1038/nrd3745.
[2] T. Ryhänen, J.M.T. Hyttinen, J. Kopitz, K. Rilla, E. Kuusisto, E. Mannermaa, J. Viiri,
C.I. Holmberg, I. Immonen, S. Meri, J. Parkkinen, E. Eskelinen, H. Uusitalo,
A. Salminen, K. Kaarniranta, Crosstalk between Hsp70 molecular chaperone , ly-
sosomes and proteasomes in autophagy-mediated proteolysis in human retinal
pigment epithelial cells, Cell Cult. Treat. 13 (2009) 3616–3631 https://doi.org/10.
1111/j.1582-4934.2008.00577.x.
[3] D.A. Ferrington, D. Sinha, K. Kaarniranta, Defects in retinal pigment epithelial cell
proteolysis and the pathology associated with age-related macular degeneration,
Prog. Retin. Eye Res. 51 (2016) 69–89 https://doi.org/10.1016/j.preteyeres.2015.
09.002.
[4] A. Subrizi, E. Toropainen, E. Ramsay, A.J. Airaksinen, K. Kaarniranta, A. Urtti,
Oxidative stress protection by exogenous delivery of rhhsp70 chaperone to the
retinal pigment epithelium (RPE), a possible therapeutic strategy against RPE de-
generation, Pharm. Res. (N. Y.) 32 (2015) 211–221 https://doi.org/10.1007/
s11095-014-1456-6.
[5] R. Bisht, A. Mandal, J.K. Jaiswal, I.D. Rupenthal, Nanocarrier mediated retinal drug
delivery: overcoming ocular barriers to treat posterior eye diseases, Wiley
Interdiscip. Rev. Nanomedicine Nanobiotechnology. 10 (2018) 1–21 https://doi.
org/10.1002/wnan.1473.
[6] N.S. Basakran, CD44 as a potential diagnostic tumor marker, Saudi Med. J. 36
(2015) 273–279 https://doi.org/10.15537/smj.2015.3.9622.
[7] M.C. Kuppner, J. Liversidge, S. McKillop-Smith, L. Lumsden, J.V. Forrester,
Adhesion molecule expression in acute and ﬁbrotic sympathetic ophthalmia, Curr.
Eye Res. 12 (1993) 923–934 https://doi.org/10.3109/02713689309020399.
[8] W.Y. Shen, M.J.T. Yu, C.J. Barry, I.J. Constable, P.E. Rakoczy, Expression of cell
adhesion molecules and vascular endothelial growth factor in experimental chor-
oidal neovascularisation in the rat 82 (1998), pp. 1063–1071 https://doi.org/10.
1136/bjo.82.9.1063.
C. Chandola, et al. Biochemistry and Biophysics Reports 18 (2019) 100642
5
[9] T. Ishimoto, H. Sugihara, M. Watanabe, H. Sawayama, M. Iwatsuki, Y. Baba,
H. Okabe, K. Hidaka, N. Yokoyama, K. Miyake, M. Yoshikawa, O. Nagano,
Y. Komohara, M. Takeya, H. Saya, H. Baba, Macrophage-derived reactive oxygen
species suppress miR-328 targeting CD44 in cancer cells and promote redox
adaptation, Carcinogenesis 35 (2014) 1003–1011 https://doi.org/10.1093/carcin/
bgt402.
[10] H. Cd, A. Somasunderam, V. Thiviyanathan, T. Tanaka, X. Li, M. Neerathilingam,
G. Lakshmana, R. Lokesh, A. Mann, Y. Peng, M. Ferrari, J. Klostergaard,
D.G. Gorenstein, Combinatorial selection of DNA thioaptamers targeted to the HA
binding, (2010), pp. 9106–9112 https://doi.org/10.1021/bi1009503.
[11] C. Chandola, S. Kalme, M.G. Casteleijn, A. Urtti, M. Neerathilingam, Application of
aptamers in diagnostics, drug-delivery and imaging, J. Biosci. 41 (2016) 535–561
https://doi.org/10.1007/s12038-016-9632-y.
[12] N.P. Liu, W.L. Roberts, L.P. Hale, M.C. Levesque, D.D. Patel, C.L. Lu, G.J. Jaﬀe,
Expression of CD44 and variant isoforms in cultured human retinal pigment epi-
thelial cells, Investig. Ophthalmol. Vis. Sci. 38 (1997) 2027–2037.
[13] M.H. Chaitin, H.S. Wortham, A.M. Zinkernagel, Immunocytochemical localization
of CD44 in the mouse retina, Exp. Eye Res. 58 (1994) (1994) 359–366 https://doi.
org/10.1006/exer.1994.1026.
[14] L. Gan, J. Wang, Y. Zhao, D. Chen, C. Zhu, J. Liu, Y. Gan, Hyaluronan-modiﬁed
core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium
cells via intravitreal injection, Biomaterials 34 (2013) 5978–5987 https://doi.org/
10.1016/j.biomaterials.2013.04.035.
[15] W. Alshaer, H. Hillaireau, J. Vergnaud, S. Ismail, E. Fattal, Functionalizing lipo-
somes with anti-CD44 aptamer for selective targeting of cancer cells, Bioconjug.
Chem. 26 (2015) 1307–1313 https://doi.org/10.1021/bc5004313.
[16] A.L. Weigel, H. Ida, S.A. Boylan, L.M. Hjelmeland, Acute hyperoxia-induced tran-
scriptional response in the mouse RPE/choroid, Free Radic. Biol. Med. 35 (2003)
465–474 https://doi.org/10.1016/S0891-5849(03)00320-4.
[17] A.L. Weigel, J.T. Handa, L.M. Hjelmeland, Microarray analysis of H2O2-, HNE-, or
tBH-treated ARPE-19 cells, Free Radic. Biol. Med. 33 (2002) 1419–1432 https://
doi.org/10.1016/S0891-5849(02)01082-1.
[18] Y. Liu, A. Beyer, R. Aebersold, On the dependency of cellular protein levels on
mRNA abundance, Cell 165 (2016) 535–550 https://doi.org/10.1016/j.cell.2016.
03.014.
[19] D. Greenbaum, K. Williams, D. Greenbaum, C. Colangelo, K. Williams, M. Gerstein,
D. Greenbaum, C. Colangelo, K. Williams, M. Gerstein, Comparing protein abun-
dance and mRNA expression levels on a genomic scale, Genome Biol. 4 (9) (2003)
117 https://doi.org/10.1186/gb-2003-4-9-117.
[20] G.C. Baltazar, S. Guha, W. Lu, J. Lim, K. Boesze-Battaglia, A.M. Laties, P. Tyagi,
U.B. Kompella, C.H. Mitchell, Acidic nanoparticles are traﬃcked to lysosomes and
restore an acidic lysosomal pH and degradative function to compromised ARPE-19
cells, PLoS One 7 (2012) 1–10 https://doi.org/10.1371/journal.pone.0049635.
[21] J.L. Bourges, S.E. Gautier, F. Delie, R.A. Bejjani, J.C. Jeanny, R. Gurny, D. BenEzra,
F.F. Behar-Cohen, Ocular drug delivery targeting the retina and retinal pigment
epithelium using polylactide nanoparticles, Investig. Ophthalmol. Vis. Sci. 44
(2003) 3562–3569 https://doi.org/10.1167/iovs.02-1068.
[22] W.L. Suen, Y. Chau, Size-dependent internalisation of folate-decorated nano-
particles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-
19 cells, J. Pharm. Pharmacol. (2013) 564–573 https://doi.org/10.1111/jphp.
12134.
[23] E.M. Eremenko, O.I. Antimonova, O.G. Shekalova, S.G. Polonik, B.A. Margulis,
I.V. Guzhova, Novel compounds that increase expression of Hsp70 and its biological
activity, Cell Tissue Biol. 4 (2010) 251–257 https://doi.org/10.1134/
S1990519X10030065.
[24] M. Bhattacharya, S. Sarkhel, J. Peltoniemi, R. Broadbridge, M. Tuomainen,
S. Auriola, A. Urtti, Diﬀerentially cleaving peptides as a strategy for controlled drug
release in human retinal pigment epithelial cells, J. Control. Release 251 (2017)
37–48 https://doi.org/10.1016/j.jconrel.2017.02.013.
[25] G. Perrot, B. Langlois, J. Devy, A. Jeanne, L. Verzeaux, S. Almagro, H. Sartelet,
C. Hachet, C. Schneider, E. Sick, M. David, M. Khrestchatisky, H. Emonard,
L. Martiny, S. Dedieu, LRP-1-CD44, a new cell surface complex regulating tumor
cell adhesion, Mol. Cell Biol. 32 (2012) 3293–3307 https://doi.org/10.1128/MCB.
00228-12.
[26] T. Kirkegaard, A.G. Roth, N.H.T. Petersen, A.K. Mahalka, O.D. Olsen, I. Moilanen,
A. Zylicz, J. Knudsen, K. Sandhoﬀ, C. Arenz, P.K.J. Kinnunen, J. Nylandsted,
M. Jäättelä, Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-asso-
ciated lysosomal pathology, Nature 463 (2010) 549–553 https://doi.org/10.1038/
nature08710.
[27] W. Knudson, G. Chow, C.B. Knudson, CD44-mediated uptake and degradation of
hyaluronan, Matrix Biol. 21 (2002) 15–23.
C. Chandola, et al. Biochemistry and Biophysics Reports 18 (2019) 100642
6
